A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

Egils Vjaters; Haresh KP; Daniel Castellano; David Olmos; Neal D. Shore; Liina Nevalaita; Testa Isabella; Kappeler Christian; Kuss Iris; Saad Fred

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

Egils Vjaters
, Haresh KP
, Daniel Castellano
, David Olmos
, Neal D. Shore
, Liina Nevalaita
, Testa Isabella
, Kappeler Christian
, Kuss Iris
, Saad Fred

University of Latvia

Ne LU

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	40
Issue number	6
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

OECD Field of Science

3. Medical and Health Sciences

Cite this

@article{9b23c179bef2465fa151bbf3e6a1d3a2,

title = "A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)",

author = "Egils Vjaters and Haresh KP and Daniel Castellano and David Olmos and \{D. Shore\}, Neal and Liina Nevalaita and Testa Isabella and Kappeler Christian and Kuss Iris and Saad Fred",

year = "2022",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE). / Vjaters, Egils; KP, Haresh; Castellano, Daniel et al.
In: Journal of Clinical Oncology, Vol. 40, No. 6, 2022.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

AU - Vjaters, Egils

AU - KP, Haresh

AU - Castellano, Daniel

AU - Olmos, David

AU - D. Shore, Neal

AU - Nevalaita, Liina

AU - Isabella, Testa

AU - Christian, Kappeler

AU - Iris, Kuss

AU - Fred, Saad

PY - 2022

Y1 - 2022

UR - https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.TPS200

M3 - Meeting abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

UN SDGs

OECD Field of Science

Other files and links

Cite this